The FDA Oncologic Drugs Advisory Committee July 14 voted 12-0 to recommend approval for belantamab mafodotin for relapsed or refractory multiple myeloma.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
